If you have been reading about Cyclic AMP and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake in single-use vials |
| Solubility class | Freely soluble in water | Reconstituted with sterile diluent before injection |
| Typical storage temperature | 2 to 8 degrees Celsius | Before reconstitution; protect from light |
| Typical analytical method | Reversed-phase high-performance liquid chromatography | Purity and related-substance testing |
| Identity confirmation | Mass spectrometry | Observed mass near 5.1 kDa for the intact peptide |
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Put simply, the biggest limits of applying such transplantation more widely were not cost or surgical skill (as formidable as those are) but rather the problem of allograft rejection and the scarcity of donor organs. Ciclosporin was a major advancement against the rejection part of the challenge.
Acanthamoeba infection Amebiasis cutis Ant sting Arachnidism Baker's itch Balamuthia infection Bedbug infestation (bedbug bite, cimicosis) Bee and wasp stings Blister beetle dermatitis Bombardier beetle burn Bristleworm sting Centipede bite Cheyletiella dermatitis Chigger bite Coolie itch Copra itch Coral dermatitis Creeping eruption (cutaneous larva migrans) Cutaneous leishmaniasis (Aleppo boil, Baghdad boil, bay sore, Biskra button, Chiclero ulcer, Delhi boil, Kandahar sore, Lahore sore, leishmaniasis tropica, oriental sore, pian bois, uta) Cysticercosis cutis Demodex folliculitis, usually caused by the Demodex folliculorum mite Dogger Bank itch Dracunculiasis (dracontiasis, guinea worm disease, Medina worm) Echinococcosis (hydatid disease) Elephantiasis tropica (elephantiasis arabum) Elephant skin Enterobiasis (oxyuriasis, pinworm infection, seatworm infection) Erisipela de la costa Feather pillow dermatitis Funnel web spider bite Gamasoidosis Gnathostomiasis (larva migrans profundus) Grain itch (barley itch, mattress itch, prairie itch, straw itch) Grocer's itch Head lice infestation (cooties, pediculosis capitis) Hookworm disease (ancylostomiasis, ground itch, necatoriasis, uncinariasis) Human trypanosomiasis Hydroid dermatitis Irukandji syndrome Jellyfish dermatitis Ked itch Larva currens Latrodectism (widow spider bite) Leech bite Leopard skin Lepidopterism (Caripito itch, caterpillar dermatitis, moth dermatitis) Lizard skin Loaiasis (Calabar swelling, fugitive swelling, loa loa, tropical swelling) Loxoscelism (brown recluse spider bite, necrotic cutaneous loxoscelism) Mal morando Millipede burn Mosquito bite Mucocutaneous leishmaniasis (espundia, leishmaniasis Americana) Myiasis Nairobi fly dermatitis (Kenya fly dermatitis, Nairobi eye) Nematode dermatitis Norwegian scabies (crusted scabies) Onchocerciasis Ophthalmia nodosa Paederus dermatitis Pediculosis corporis (pediculosis vestimenti, Vagabond's disease) Pediculosis pubis (crabs, phthirus pubis, phthirus pubis, pubic lice) Pneumocystosis (often classified as fungal) Portuguese man-of-war dermatitis Post-kala-azar dermal leishmaniasis (post-kala-azar dermatosis) Protothecosis Pulicosis (flea bites) Reduviid bite Scabies (itch mite infestation, seven-year itch) Scorpion sting Sea anemone dermatitis Seabather's eruption (sea lice) Sea urchin injury Seaweed dermatitis Snake bite Sowda Sparganosis Spider bite Stingray injury Swimmer's itch (cercarial dermatitis, schistosome cercarial dermatitis) Tarantula bite Tick bite Toxoplasmosis Trichinosis Trichomoniasis Tungiasis (bicho de pie, chigoe flea bite, jigger bite, nigua, pique) Visceral leishmaniasis (dumdum fever, kala-azar) Visceral schistosomiasis (bilharziasis) Viscerotropic leishmaniasis Wheat warehouse itch
According to the DSM, it "is the more specific DSM-5 diagnostic category in which erectile dysfunction persists for at least 6 months and causes distress in the individual." The ICD-10, to which the DSM refers regarding Erectile dysfunction, lists it under Failure of genital response (F52.2). The latest edition of the ICD – namely, the ICD-11 – lists the condition as Male erectile dysfunction (HA01.1).
Reports of widespread adulteration of Chinese animal feed with melamine have raised the issue of melamine contamination in the human food supply both in China and abroad. In April 2007, the U.S. Food and Drug Administration (FDA) subjected all vegetable proteins imported from China, intended for human or animal consumption, to detention without physical examination, including: wheat gluten, rice gluten, rice protein, rice protein concentrate, corn gluten, corn gluten meal, corn by-products, soy protein, soy gluten, proteins (includes amino acids and protein hydrolysates), and mung bean protein. Officials from the FDA and U.S. Department of Agriculture said that between 2.5 and 3 million Americans had consumed chickens that had consumed feed containing contaminated vegetable protein from China. Reports that melamine has been added as a binder in animal feed manufactured in North America raised the possibility that harmful melamine contamination might not be limited to China. In 2008, Sanlu Group had to recall baby formula because it was contaminated with melamine. Around 294,000 babies in China became ill after drinking the milk; at least six died. As of July 2010, Chinese authorities were still reporting some seizures of melamine-contaminated dairy product in some provinces, though it was unclear whether these new contaminations constituted wholly new adulterations or were the result of illegal reuse of material from the 2008 adulterations.
== Treatment == While the disease is not reversible, treatments can slow further worsening. This may include the use of corticosteroids or immunosuppressive medication which may have an effect on the ability to receive a lung transplant if offered. If patients have difficulty breathing (hypoxemia) oxygen can be supplemented. Routine vaccinations are recommended for patients with chronic lung disease to prevent complications from secondary infections due to pneumonia and influenza.
Sources: en.wikipedia.org
== History == 4-AcO-DMT and several other esters of psilocin were patented on January 16, 1963, by Sandoz via Albert Hofmann and Franz Troxler. The drug's chemical synthesis was improved by David E. Nichols and colleagues in 1999 and it was suggested as a more economical and accessible alternative to psilocybin for use in scientific research. 4-AcO-DMT was first detected as a designer drug in Europe in 2009. It became increasingly prevalent as a recreational drug in the 2010s and has been the most commonly used novel tryptamine. In the 2020s, 4-AcO-DMT became widely encountered in the form of mushroom edibles in the United States as an alternative to psilocybin and psilocybin-containing mushrooms.
If the newborn seems to need help in latching on, the mother should focus on helping the infant by bringing their chin to the breast first. This facilitates a deep, asymmetric latch, and also helps the infant extend their neck and tilt their forehead back to maintain this deep latch and ease the swallowing process.
An FA disciplinary commission found Wenger guilty; he received a 12-match touchline ban and a fine of four weeks' salary. He successfully appealed the ban, but was reprimanded and fined £10,000 for his actions. Following the 2007 Football League Cup Final, he called a linesman a liar, for stating Emmanuel Adebayor aimed a punch at Chelsea's Frank Lampard. This led to an investigation by the FA, a fine of £2,500 and a warning. In March 2011, Wenger was charged with improper conduct by UEFA, over comments made to referee Massimo Busacca, after his team's defeat to Barcelona. He was fined €10,000 and suspended for one UEFA club competition match; however, the ban was later extended to a further two games, after Wenger was found guilty of communicating with Arsenal's bench while serving a touchline ban against Udinese. A year later, Wenger was charged for post-match comments made about referee Damir Skomina, in Arsenal's defeat to Milan in the Champions League. He was fined £33,000 and handed a three-match touchline ban in the competition.
The new 16th district is entirely within El Paso County, taking in El Paso and such surrounding suburbs as Socorro, Horizon City, and Anthony. The incumbent is Democrat Veronica Escobar, who was re-elected with 59.5% of the vote in 2024. In 2024, Kamala Harris won 57.4% of the vote in this heavily Hispanic district, where Colin Allred also won with 58.4% of the vote.
In tellurium-induced demylenation with no axon degeneration, nerve crush with axon degeneration, and nerve transection with axon degeneration an increase in MCP-1 mRNA expression followed by an increase in macrophage recruitment occurred. In addition varying levels of MCP-1 mRNA expression also had an effect. Increased MCP-1 mRNA levels correlated positively with an increase in macrophage recruitment. Furthermore, in situ hybridation determined that the cellular source of MCP-1 was Schwann cells. Schwann cells play an important role in not only producing neurotrophic factors such as nerve growth factor (NGF) and ciliary neurotrophic factor (CNTF), which promote growth, of both the damaged nerve and supporting Schwann cells, but also producing neurite promoting factors, which guide the growing axon, both of which are discussed below.
Sources: en.wikipedia.org
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.
The primary measure is usually a cross-sectional abdominal scan that separates internal fat from fat just under the skin. Waist circumference and body weight are recorded as secondary measures because they are easy to obtain but do not distinguish the two fat compartments. Hormone and metabolic blood tests are collected alongside the imaging.
Available follow-up data indicate that visceral fat drifts back toward pretreatment levels once injections stop. The change is therefore best described as treatment-dependent rather than permanent. Investigators continue to debate whether intermittent or repeated courses would preserve any benefit.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.